GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE325nnn/GSE325548/primaryOK200TranscriptomicsMus musculusExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE325548GEOGSEfalseTime-resolved transcriptomic profiling of surgical wounds identifies stage-specific therapeutic targets for residual ovarian cancerBackground: The optimal timing of adjuvant chemotherapy after cytoreductive surgery in epithelial ovarian cancer remains uncertain, and perioperative wound-healing responses may transiently create a pro-tumorigenic and drug-resistant microenvironment. This study aimed to characterize time-dependent wound-induced transcriptomic alterations and to identify pharmacologic agents capable of reversing these responses. Methods: An ID8 murine ovarian cancer model was used to compare no treatment, anesthesia alone, and anesthesia plus surgical wounding mimicking futile laparotomy. Tumors were collected at baseline, 1 day (T1), 1 week (T2), and 2 weeks (T3) after intervention. RNA sequencing was performed, and wound-specific differentially expressed genes (WsDEGs) were defined by excluding anesthesia- and progression-related signatures. Functional enrichment analyses were conducted, followed by transcriptome-based drug repurposing using the REMEDY platform to identify compounds predicted to reverse wound-induced gene expression profiles. Results: Surgical wounding significantly increased tumor burden at T1. Transcriptomic analyses revealed distinct, time-dependent wound-associated programs. At T1, WsDEGs were enriched in inflammatory signaling, coagulation, angiogenesis, and immune cell migration, with Vorinostat and Homohar-ringtonine identified as top candidates to counteract these signatures. At T2, pathways related to cell survival, adhesion, and morphogenesis predominated, with LY-2090314, Artesunate, and Birinapant emerging as potential modulators. At T3, cell-cycle regulation and lipid metabolic pathways were dominant, and Fulvestrant, Atorvastatin, Imatinib, and ABT-737 were predicted to inhibit these processes. Conclusions: Perioperative sur-gical wounding induces dynamic, stage-specific transcriptomic programs that may promote ovarian cancer progression and alter drug responsiveness. These findings support time-adapted perioperative pharmacologic strategies to optimize postoperative cancer therapy.2026/03/27GSE325548GSM9608249GSM9608280GSM9608281GSM9608260GSM9608282GSM9608283GSM9608261GSM9608262GSM9608284GSM9608285GSM9608263GSM9608286GSM9608264GSM9608265GSM9608287GSM9608288GSM9608266GSM9608289GSM9608267GSM9608268GSM9608269GSM9608259GSM9608290GSM9608291GSM9608292GSM9608270GSM9608271GSM9608293GSM9608294GSM9608272GSM9608250GSM9608251GSM9608295GSM9608273GSM9608274GSM9608252GSM9608296GSM9608275GSM9608253GSM9608254GSM9608276GSM9608277GSM9608255GSM9608278GSM9608256GSM9608257GSM9608279GSM96082589185325548Mus musculus